eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors
SCImago Journal & Country Rank

3/2018
vol. 15
 
Share:
Share:
more
 
 
abstract:
Short communication

Carotid baroreceptor activation therapy for resistant hypertension and heart failure: a report of two cases

Ahmet Baris Durukan, Hasan Alper Gurbuz

Kardiochirurgia i Torakochirugia Polska 2018; 15 (3): 200-203
Online publish date: 2018/09/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Introduction

A vast number of drugs and treatment strategies have been approved for treatment of hypertension in the last three decades. However, despite these advances, there is still a reported prevalence of 3 to 30% of treatment-resistant hypertension (TRH) [1]. According to 2013 ESH/ESC guidelines for the management of arterial hypertension, TRH is defined as an office measurement of systolic blood pressure (BP) > 140 mm Hg and/or diastolic BP of > 90 mm Hg despite appropriate life-style measures and antihypertensive treatment including a diuretic (at full dose) and two other antihypertensive drugs of different classes at adequate doses [2]. Following catheter-based renal denervation therapy, the concept of TRH has gained popularity and specific therapies have emerged including carotid baroreceptor activation therapy (BAT).
Similar to the concept of TRH, despite enormous advances in surgical and medical treatment of heart failure (HF), 25 to 35% of cases remain in NYHA class III. These patients often experience moderate to severe heart failure symptoms and have a low quality of life, causing increased health care costs. We already know that adrenergic activation and parasympathetic denervation have a role in symptom occurrence and disease progression [3]. With this rationale, carotid BAT has emerged as a therapeutic strategy in treatment of heart failure.
Here, we report two cases, one with resistant hypertension and the other with heart failure treated with surgical BAT.
Written informed consent was obtained from each patient for submission of the report.

Case reports

Case 1

A 52-year-old male patient was being followed up for hypertension for 10 years and TRH was diagnosed one year ago. He had coronary artery disease and type 2 diabetes mellitus. He had a triple vessel bypass 10 years ago and repeat percutaneous coronary intervention (PCI) was performed for left anterior descending artery (LAD) and right coronary arteries in the following years. He was on a b-blocker and angiotensin receptor antagonist/diuretic combination. His ambulatory blood pressure monitoring (ABPM) record (Ambulatory Blood Pressure Monitor, Model: ABPM50, Contec Medical Systems Co., Ltd, People’s Republic of China) revealed a mean systolic BP of 155 mm Hg and diastolic BP of 100 mm Hg despite therapy. He was scheduled for carotid baroreflex activation therapy (BAT) and surgical insertion was performed...


View full text...
references:
Rimoldi SF, Messerli FH, Bangalore S, Schrerrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015; 36: 2686-2695.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. ACC Heart Fail 2015; 3: 487-496.
Courand PY, Feugier P, Workineh S, Harbaoui B, Bricca G, Lantelme P. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review. Arch Cardiovasc Dis 2014; 107: 690-696.
Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barositm neo Trial. J Am Soc Hypertens 2012; 6: 270-276.
Gronda E, Seravalle G, Brambilla G, Constantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014; 16: 977-983.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe